Agree mate. Further from my post
In 2017 PingAn had 370,000 telehealth consults per day and was growing at +100% per year (this is not a typo).
We are told that 30-50% of all consults are for respiratory disease. That's around 100k - 200k consults for respiratory disease per day and at only $5/test this is USD 500k - 1m revenue per day!
With these assumptions:
$5/test = 500k/day base case
= 182M revenue/year
= 91M earnings if we assume 50% goes to taxes, overheads and R&D
= around 1.8B market cap based on very conservative PE of 20x and fully diluted (~800m shares
= $2.26/share
I will be very surprised if we're not taken out way before then.
Some profit taking happening now, but when the market begins to understand the magnitude of the opportunity, the sp will kick.
As Tony said in the con call...this is a game changer for the Telehealth industry.
- Forums
- ASX - By Stock
- RAP
- Ann: Positive Results for Australian Prospective Paediatric Study
Ann: Positive Results for Australian Prospective Paediatric Study, page-90
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
-
- There are more pages in this discussion • 280 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)